Evaluating Targeted Radionuclide Therapy (Lu-177 PSMA) Radiation Dose to Tumors and Organs in Prostate Cancer Patients with Compromised Kidney and Bone Marrow Function
This phase II trial evaluates the dose of lutetium (Lu)-177 prostate-specific membrane antigen (PSMA) absorbed in the tumor and organs of prostate cancer patients whose kidneys and/or bone marrow are not working properly (compromised). Lu-177 PSMA, a type of radionuclide therapy, binds to a protein called PSMA, which is found on some prostate tumor cells. It gives off radiation that may kill the tumor cells. Overall, toxicities related to this therapy have been low grade, however, long term effects on kidneys and blood and bone marrow are not known. Single photon emission computed tomography (SPECT) is a special type of computed tomography (CT) scan in which a small amount of radioactive drug is injected into a vein and a scanner is used to make detailed images of areas inside the body where the radioactive material is taken up by the cells. SPECT can give information about blood flow to tissues and chemical reactions (metabolism) in the body. CT utilizes x-rays that traverse the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in patient’s body. SPECT/CT scans combine both modalities into a single scan during the examination. The data from the SPECT/CT scans may help researchers learn how much Lu-177 PSMA is absorbed by the tumor and organs to better personalize radiation dosing in prostate cancer patients with compromised kidney and bone marrow function.